Training of Academic Surgical Oncologists

Jennifer Wargo, M.D.
Principal Investigator 

Ashley Holder, M.D. 
Associate Program Director

Matthew H.G. Katz, M.D.
Surgical Oncology Department Chair

Jennifer Chen, M.D.
Baylor College of Medicine
Second-Year Fellow

Neha Malik, M.D.
UTHealth Houston
Second-Year Fellow

Laurence Diggs, M.D.
The University of Texas MD Anderson Cancer Center
First-Year Fellow 

Kever Lewis, M.D.
University of Mississippi
First-Year Fellow

George Calin, M.D., Ph.D.
Professor, Department of Translational Molecular Pathology
Co-Director, The RNA Interference and non-codingRNA Center
Co-Director, MD/PhD Program, The University of Texas, Graduate School of Biomedical Sciences

Dr. George Calin's main research interests are: 1) the involvement of non-coding RNAs in human diseases in general and of microRNAs in human cancers in particular, 2) the study of familial predisposition to human cancers, 3) the identification of ncRNA biomarkers in body fluids, and 4) the development of new RNA-basedtherapeutic options for cancer patients. Visit the Calin Lab webpage here.

Relevant Publications: 
Loss of p53 drives neuron reprogramming in head and neck cancer. Amit M, Takahashi H, Dragomir MP, Lindemann A, Gleber-Netto FO, Pickering CR, Anfossi S, Osman AA, Cai Y, Wang R, Knutsen E, Shimizu M, Ivan C, Rao X, Wang J, Silverman DA, Tam S, Zhao M, Caulin C, Zinger A, Tasciotti E, Dougherty PM, El-Naggar A, Calin GA, Myers JN. Nature. 2020 Feb;578(7795):449-454. doi: 10.1038/s41586-020-1996-3. Epub 2020 Feb 12. PMID: 32051587 

Michael Davies, M.D.
Professor & Chairman, Department of Melanoma Medical Oncology
Joint Appointment, Departments of Translational Molecular Pathology and Genomic Medicine
Anne and John Mendelsohn Chair for Cancer Research

Dr. Michael Davies is a physician-scientist whose research utilizes integrated approaches to study the regulation and clinical significance of oncogenic signaling networks in cancer, with particular focus on therapeutic resistance and CNS metastasis. His research approaches utilize both preclinical models and clinical specimens to address key questions in these and other research areas.

Relevant Publications: 
Changes in outcomes and factors associated with survival in melanoma patients with brain metastases. Hasanov M, Milton DR, Davies AB, Sirmans E, Saberian C, Posada EL, Opusunju S, Gershenwald JE, Torres-Cabala CA, Burton EM, Colen RR, Huse JT, Glitza Oliva IC, Chung C, McAleer MF, McGovern SL, Yeboa DN, Kim BYS, Prabhu SS, McCutcheon IE, Weinberg JS, Lang FF, Tawbi HA, Li J, Haydu LE, Davies MA, Ferguson SD. Neuro Oncol. 2023 Jul 6;25(7):1310-1320. doi: 10.1093/neuonc/noac251. PMID: 36510640

Melanoma Brain Metastasis: Biology and Therapeutic Advances. Hasanov M, Acikgoz Y, Davies MA. Hematol Oncol Clin North Am. 2024 Oct;38(5):1027-1043. doi: 10.1016/j.hoc.2024.05.008. Epub 2024 Jun 5. PMID: 38845301

Sharon Giordano, M.D.
Department Chair, Department of Health Services Research
Professor of Medicine and Internist, Department of Breast Medical Oncology
Colin Powell Chair for Cancer Research

Dr. Sharon Giordano's research interests include quality of health care delivery, health equity, and outcomes among people with breast cancer. She has successfully mentored prior trainees on NCI K awards, ASCO Young Investigator Grants and DOD grants. Her work in mentoring was recognized by the Cancer Medicine Mentor of the Year Award and the MD Anderson President's Faculty Excellence Award in Education and Mentorship. In 2024, she received ASCO’s Hologic Women Who Conquer Cancer Mentorship Award.

Kelly Hunt, M.D.
Professor and Chair, Department of Breast Surgical Oncology
Joint Appointments in Experimental Radiation Oncology and Surgical Oncology

Dr. Kelly Hunt’s research is focused on the identification of predictive biomarkers to provide most effective therapeutic strategies based on tumor biology. In the clinical setting, the aim of her research is to determine whether less invasive surgical procedures can provide effective treatment strategies for patients with breast cancer and soft tissue sarcomas. The goal of her translational research is to develop novel treatment strategies targeting cell cycle regulation in sarcomas and breast cancer.

Relevant Publications: 
Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Karakas C, Francis AM*, Ha MJ, Wingate HF, Meena RA, Yi M, Rasaputra KS, Barrera AMG, Arun B, Do KA, Sahin A, Keyomarsi K, Hunt KK. Ann Surg. 2021 Aug 1;274(2):e150-e159. doi: 10.1097/SLA.0000000000003551.PMID: 31436549 

CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. Francis AM*, Alexander A, Liu Y, Vijayaraghavan S, Low KH, Yang D, Bui T, Somaiah N, Ravi V, Keyomarsi K, Hunt KK. Mol Cancer Ther. 2017 Sep;16(9):1751-1764. doi: 10.1158/1535-7163.MCT-17-0040. Epub 2017 Jun 15. PMID: 28619757 
 

Eugene Koay, M.D.
Professor, Department of Gastrointestinal Radiation Oncology

Dr. Eugene Koay focuses on hepatobiliary and pancreatic cancer research. This
research spans clinical and translational sciences, including therapeutic clinical trials for cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer, as well as early detection studies that use radiomics and artificial intelligence. He collaborates with physicists and mathematicians to understand the phenomena observed in his clinical and translational research studies.

Relevant Publications: 
Definitive Liver Radiotherapy for Intrahepatic Cholangiocarcinoma with Extrahpatic Metastase. De B, Upadhyay R, Liao K, Kumala T, Shi C, Dodoo G, Abi Jaoude J, Corrigan KL, Manzar GS, Marqueen KE, Bernard V, Lee SS, Raghav KPS, Vauthey JN, Tzeng CD, Tran Cao HS, Lee G, Wo JY, Hong TS, Crane CH, Minsky BD, Smith GL, Holliday EB, Taniguchi CM, Koong AC, Das P, Javle M, Ludmir EB, Koay EJ. Liver Cancer. 2023 Mar 16;12(3):198-208. doi: 10.1159/000530134. eCollection 2023 Aug. PMID: 37593365

Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling. Butner JD, Martin GV, Wang Z, Corradetti B, Ferrari M, Esnaola N, Chung C, Hong DS, Welsh JW, Hasegawa N, Mittendorf EA, Curley SA, Chen SH, Pan PY, Libutti SK, Ganesan S, Sidman RL, Pasqualini R, Arap W, Koay EJ, Cristini V. Elife. 2021 Nov 9;10:e70130. doi: 10.7554/eLife.70130. PMID: 34749885
 

Anirban Maitra, M.D.
Professor, Department of Pathology and Translational Molecular Pathology

Dr. Anirban Maitra is the Scientific Director of the Sheikh Ahmed Pancreatic Cancer Research since August 2013. He is the Principal Investigator of an NCI-funded laboratory dedicated to pancreatic cancer research. The arc of his research career has been defined by contributions made in the spheres of genetics and molecular pathology of pancreatic cancer and its precursor lesions, in both human and cognate mouse models of pancreatic neoplasia. He has trained over three dozen postdoctoral fellows and graduate students, many of whom are now in independent faculty positions in the United States or worldwide. 

Relevant Publications: 
Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. Jaewon J Lee, Vincent Bernard, Alexander Semaan, Maria E Monberg, Jonathan Huang, Bret M Stephens, Daniel Lin, Kimal I Rajapakshe, Brian R Weston, Manoop S Bhutani, Cara L Haymaker, Chantale Bernatchez, Cullen M Taniguchi, Anirban Maitra, Paola A Guerrero. Clin Cancer Res. 2021 Nov 1;27(21):5912-5921. doi: 10.1158/1078-0432.CCR-20-3925. Epub 2021 Aug 23. PMID: 34426439.

Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project. Alexander Semaan, Vincent Bernard, Justin Wong, Yuki Makino, Daniel B Swartzlander, Kimal I Rajapakshe, Jaewon J Lee, Adam Officer, Christian Max Schmidt, Howard H Wu, Courtney L Scaife, Kajsa E Affolter, Daniela Nachmanson, Matthew A Firpo, Michele Yip-Schneider, Andrew M Lowy, Olivier Harismendy, Subrata Sen, Anirban Maitra, Yasminka A Jakubek, Paola A Guerrero. Cancer Res Commun. 2023 Oct 10;3(10):2062-2073. doi: 10.1158/2767-9764.CRC-22-0419. PMID: 37721516.

Florencia McAllister, M.D.
Associate Professor, Department of Clinical Cancer Prevention
Joint Appointment, Associate Professor, Department of Gastrointestinal (GI) Medical Oncology

Dr. Florencia McAllister has a strong commitment to research and is passionate
about education. She is a member of the UT/MDACC Graduate School, where she co-directed the Cancer Metastasis course and has been an instructor in Immunology Courses. She has an open-door policy in her laboratory which allows close mentoring and hands-on involvement and has resulted in high productivity in trainees. The McAllister Laboratory studies the interplay between the immune system, microbes and tumors behavior. They are fundamentally interested in understanding how those interactions ultimately determine tumor initiation, progression, therapies responses and metastasis. She has an extensive record of mentoring high school, undergraduate, graduate students, and postdoctoral fellows/research investigators/research scientists, international visiting scholars, and medical students including those that are underrepresented in the field of biomedical research. 

Relevant Publications: 
Germline Testing Identifies Pathogenic/Likely Pathogenic Variants in Patients with Pancreatic Neuroendocrine Tumors. Mohindroo C, Baydogan S, Agarwal P, Wright RD, Prakash LR, Mork ME, Klein AP, Laheru DA, Maxwell JE, Katz MHG, Dasari A, Kim MP, He J, McAllister F, De Jesus-Acosta A. Cancer Prev Res (Phila). 2024 Jul 2;17(7):335-342. doi: 10.1158/1940-6207.CAPR-23-0483. PMID: 38662083.

Bacterial and fungal characterization of pancreatic adenocarcinoma from Endoscopic Ultrasound-guided biopsies. Wright RD, Bartelli TF, Baydogan S, White JR, Kim MP, Bhutani MS, McAllister F. Front Immunol. 2023 Oct 13;14:1268376. doi: 10.3389/fimmu.2023.1268376. PMID: 37901238; PMCID: PMC10611524.

Transient CA19-9 Elevation Post-COVID-19 Vaccine and Infection: A Case Series. Baydogan S, Wright R, Kottoor RT, Kim M, Bhutani MS, McAllister F. Gastro Hep Adv. 2023 Jun 30;2(7):946-947. doi: 10.1016/j.gastha.2023.06.008. PMID: 39130759; PMCID: PMC11307509.

Funda Meric-Bernstam, M.D. 
Chair, Department of Investigational Cancer Therapeutics
Professor, Department of Breast Surgical Oncology
Medical Director, Department of Khalifa Institute for Personalized Cancer Therapy
Nellie B. Connally Chair in Breast Cancer, Department of Investigational Cancer Therapeutics

Dr. Funda Meric-Bernstam has a basic and translational research program that is focused on molecular therapeutics, to delineate the mechanism of action of each agent targeting this pathway and the molecular alterations useful to prospectively identify patients who will benefit most from each agent, and optimal combination therapies with targeted therapies and novel immune modulators. She is an active clinical trialist focused on Phase I trials, and rationale combinations, biomarker-driven therapy, and immune-oncology.

Relevant Publications:
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Timothy P DiPeri, Kurt W Evans, Maria Gabriela Raso, Ming Zhao, Yasmeen Q Rizvi, Xiaofeng Zheng, Bailiang Wang, Bryce P Kirby, Kathleen Kong, Michael Kahle, Timothy A Yap, Ecaterina E Dumbrava, Jaffer A Ajani, Siqing Fu, Khandan Keyomarsi, Funda Meric-Bernstam. Clin Cancer Res. 2023 Nov 1;29(21):4385-4398. PMID: 37279095. PMCID: PMC10618648.

Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Timothy P DiPeri, Kurt W Evans, Bailiang Wang, Ming Zhao, Argun Akcakanat, Maria Gabriela Raso, Yasmeen Q Rizvi, Xiaofeng Zheng, Anil Korkut, Kaushik Varadarajan, Burak Uzunparmak, Ecaterina E Dumbrava, Shubham Pant, Jaffer A Ajani, Paula R Pohlmann, V Behrana Jensen, Milind Javle, Jordi Rodon, Funda Meric-Bernstam. Cancer Discov. 2024 May 1;14(5):828-845. PMID:38358339. PMCID: PMC11064988.

Convergent MAPK pathwayalterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. Timothy P DiPeri, Ming Zhao, Kurt W Evans, Kaushik Varadarajan, Tyler Moss, Stephen Scott, Michael P Kahle, Charnel C Byrnes, Huiqin Chen, Sunyoung S Lee, Abdel-Baset Halim, Hiroshi Hirai, Volker Wacheck, Lawrence N Kwong, Jordi Rodon, Milind Javle, Funda Meric-Bernstam. J Hepatol. 2024 Feb;80(2):322-334. PMID: 37972659.

Anthony Lucci, M.D.
Professor, Department of Breast Surgical Oncology and Surgical Oncology

Dr. Anthony Lucci is a Marvin M Romsdahl MD PhD Endowed Professor and the Deputy Director of the Inflammatory Breast Cancer program. He has a research program focused on using a minimally invasive, liquid biopsy approach designed to detect cancer earlier, identify patients who are at high risk for disease relapse, monitor patient response throughout treatment, and identify novel targets for therapy. This includes a comprehensive analysis of multiple markers including circulating tumor cells, circulating tumor DNA, extracellular vesicles, and proteins. Much of Dr. Lucci's work has been in breast cancer and melanoma investigating the utility and role of circulating tumor cells and circulating tumor DNA as predictive and prognostic biomarkers. View the Lucci Lab webpage.

Relevant Publications:
Presence of molecular residual disease after pathologic complete response among patients with inflammatory breast cancer. Jennifer H. Chen, Salyna Meas, Vanessa N. Sarli, Negar Koupaei, Joshua Upshaw, Dhruvajyoti Roy, Vicente Valero, Wendy A. Woodward, and Anthony Lucci. JCO 42, 3044-3044(2024). DOI:10.1200/JCO.2024.42.16_suppl.3044. 

Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA. Chen, J.H., Addanki, S., Roy, D. BMC Cancer 24, 1016 (2024). https://doi.org/10.1186/s12885-024-12689-6. 

Low Rates of Local-Regional Recurrence Among Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy. Adesoye, T., Everidge, S., Chen, J. et al. Ann Surg Oncol 30, 6232–6240 (2023). https://doi.org/10.1245/s10434-023 13906-5. 

Matthew H.G. Katz, M.D.
Professor, Department of Surgical Oncology

Dr. Mathew H.G. Katz is Professor and Chair of the Department of Surgical Oncology. His clinical and research interests focus on the care of patients with pancreatic cancer. He has served as the national PI of two cooperative group studies of the effects of preoperative therapy on patients with advanced pancreatic cancer and has led multiple investigator-initiated trials within the institution.


 

Relevant Publications:
Patient-Reported Adverse Events During Neoadjuvant Therapy in a Phase 2 Borderline Resectable Pancreatic Cancer Clinical Trial (Alliance A021501). Snyder RA, Dueck AC, Fruth B, Shi Q, Hubbard JM, Herman JM, O'Reilly EM, Katz MHG. Annals of Surgery.. 2023 Jun; PMID: 37334719.

Communicating value: Use of a Novel Framework in the Assessment of an Enhanced Recovery Initiative. Allen CJ, Thaker NG, Prakash L, Kruse BC,
Feeley TW, Kaplan RS, Huey R, Frank SJ, Aloia TA, Gottumukkala V, Katz MHG. Ann Surg. 2021 Jan 01; 273(1):e7-e9. PMID: 32568750.

Michael Kim, M.D.
Associate Professor, Department of Surgical Oncology
Associate Professor (Joint Faculty), Department of Genetics

Dr. Michael Kim joined the Department of Surgical Oncology to establish a research program in pancreatic cancer. He has interests in the management of cystic neoplasms of the pancreas and runs the Pancreatic Cyst Clinic at the University of Texas MD Anderson Cancer Center.

Scott Kopetz, M.D., Ph.D.
Professor and Associate VP, Translational Research

Dr. Scott Kopetz is the contact PI for the institution’s Gastrointestinal SPORE, co-leader of the CCSG GI Program and the Colorectal Cancer Moon Shot. He is the Medical Director of the MDACC TRACTION platform dedicated to rapid translational oncology research. He is also the Vice-Chair for Colorectal Cancer Research for the NRG Cooperative group. He is the principal investigator of several practice-changing clinical trials, including trials for patients with BRAF-mutated colorectal cancer that led to new standards of care. View the Kopetz Laboratory page here.

Lawrence Kwong, Ph.D.
Associate Professor, Department of Translational Molecular Pathology

The Kwong Laboratory is focused on generating novel therapies for cholangiocarcinoma, melanoma, and colorectal cancer by uniting human sample analyses with mouse models and bioinformatics to model targetable networks for combination therapy. Our laboratory is highly translational in nature with an emphasis on in vivo drug efficacy, with the goal of improving drug regimens for clinical use, with the ultimate goal of extending patient survival.




Relevant Publications:
Generation of An Endogenous FGFR2-BICC1 Gene Fusion/58 Megabase Inversion Using Single-Plasmid CRISPR/Cas9 Editing in Biliary Cells. Reicher A, Harris AL, Prinz F, Kiesslich T, Wei M, Öllinger R, Rad R, Pichler M, Kwong LN. Int J Mol Sci. 2020 Apr 2;21(7):2460. doi: 10.3390/ijms21072460.
 

Anil Sood, M.D.
Professor, Department of Gynecologic Oncology and Reproductive Medicine
Vice Chair for Translational Research, Departments of Gynecologic Oncology and Cancer Biology
Co-Director, Center for RNA Interference and Non-Coding RNA

Dr. Anil Snood’s research has focused on developing new therapies aimed at the tumor microenvironment, with a particular focus on understanding mechanisms of adaptive resistance to anti-angiogenesis drugs and developing novel therapies to enhance such therapy; several of these have been translated into clinical trials. He also focuses on understanding mechanisms of metastasis, especially in understanding how tropism for specific organ sites occurs. Other projects focus on understanding the mechanisms of RNA interference and developing new approaches for using non-coding RNAs for therapy using biocompatible delivery systems. View the Sood Laboratory page here.

Relevant Publications:
Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L. LaFargue CJ, Amero P, Noh K, Mangala LS, Wen Y, Bayraktar E, Umamaheswaran S, Stur E, Dasari SK, Ivan C, Pradeep S, Yoo W, Lu C, Jennings NB, Vathipadiekal V, Hu W, Chelariu-Raicu A, Ku Z, Hui D, Xiong W, Choi HJ, Hu M, Kiyama T, Mao CA, Ali-Fehmi R, Birrer MJ, Liu J, Zhang N, Lopez-Berestein G, de Franciscis V, An Z, Sood AK (2023). Nature Communications 14, 2407; https://doi.org/10.1038/s41467-023-36910-5.

Exploiting metabolic vulnerabilities after anti-VEGF antibody therapy in ovarian cancer. Glassman D, Kim MS, Spradlin M, Badal S, Taki M, Bhattacharya P, Dutta P, Kingsley CV, Foster KI, Animasahun O, Jeon JH, Achreja A, Jayaraman A, Kumar P, Nenwani M, Wuchu F, Bayraktar E, Wu Y, Stur E, Mangala L, Lee S, Yap TA, Westin SN, Eberlin LS, Nagrath D, Sood AK (2023). iScience 26, 106020.

Rebecca Snyder, M.D.
Associate Professor, Department of Surgical Oncology
Joint Appointment, Associate Professor, Department of Health Services Research

Dr. Rebecca Snyder’s clinical practice is focused on caring for patients with pancreatic cancer, and her research efforts concentrate on patient-centered care, as well as cancer care delivery, specifically disparities related to race and social determinants of health. Dr. Snyder is actively involved in the National Clinical Trials Network Alliance for Clinical Trials in Oncology cooperative group, serving as Co-Chair of the Gastrointestinal Surgery Working Group and liaison to the Health Disparities and Cancer Care Delivery Research Committees. She is an experienced writer and has published original scientific studies and narrative medicine essays in high-impact journals including JAMA, Journal of Clinical Oncology, and JNCI. She currently serves on the Editorial Board of JCO, JCO Oncology Practice, and Annals of Surgical Oncology. Dr. Snyder has also held several national leadership positions, including Chair of the Clinical and Health Services Research Committee of the Association for Academic Surgery and Chair of the Giving Back Committee for the Society for Surgery of the Alimentary Tract.

Relevant Publications:
Surgical Considerations for Neoadjuvant Therapy for Pancreatic Adenocarcinoa. Jain AJ, Maxwell JE, Katz MHG, Snyder RA. Cancers (Basel). 2023 Aug 19;15(16):4174. doi: 10.3390/cancers15164174. PMID: 37627202 
 

Christina Roland, M.D.
Associate Professor, Department of Surgical Oncology

Dr. Roland’s research focuses on improving multimodality care for patient with soft tissue sarcoma including novel clinical trial design and quality of life studies. She serves as Principal Investigator of multiple clinical trials, including an investigator-initiated phase 2 trial evaluating neoadjuvant checkpoint blockade in sarcoma. Her research has been published in prominent journals such as Nature, Nature Cancer, Cancer, Annals of Surgical Oncology and Oncoimmunology.

Relevant Publications:
A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma. Roland CL, Nassif Haddad EF, Keung EZ, Wang WL, Lazar AJ, Lin H, Chelvanambi M, Parra ER, Wani K, Guadagnolo BA, Bishop AJ, Burton EM, Hunt KK, Torres KE, Feig BW, Scally CP, Lewis VO, Bird JE, Ratan R, Araujo D, Zarzour MA, Patel S, Benjamin R, Conley AP, Livingston JA, Ravi V, Tawbi HA, Lin PP, Moon BS, Satcher RL, Mujtaba B, Witt RG, Traweek RS, Cope B, Lazcano R, Wu CC, Zhou X, Mohammad MM, Chu RA, Zhang J, Damania A, Sahasrabhojane P, Tate T, Callahan K, Nguyen S, Ingram D, Morey R, Crosby S, Mathew G, Duncan S, Lima CF, Blay JY, Fridman WH, Shaw K, Wistuba I, Futreal A, Ajami N, Wargo JA, Somaiah N. Nat Cancer. 2024 Apr;5(4):625-641. doi: 10.1038/s43018-024-00726-z. Epub 2024 Feb 13. PMID: 38351182.

High Community-Level Social Vulnerability is Associated with Worse Recurrence-Free Survival (RFS) After Resection of Extremity and Truncal
Soft Tissue Sarcoma. Traweek RS, Lyu HG, Witt RG, Snyder RA, Nassif EF, Krijgh DD, Smith JM, Tilney GS, Feng C, Chiang YJ, Torres KE, Roubaud MJ, Scally CP, Hunt KK, Keung EZ, Mericli AF, Roland CL. Ann Surg Oncol. 2024 Jun;31(6):4138-4147. doi: 10.1245/s10434-024-15074-6. Epub 2024 Feb 23. PMID: 38396039. 
 

Hussein Tawbi, M.D., Ph.D. 
Professor and Deputy Chair, Melanoma Medical Oncology, Investigational Cancer Therapeutics

In addition to being a melanoma clinician, Dr. Hussein Tawbi develops and conducts multiple clinical trials with translational endpoints in melanoma, brain metastases, and immunotherapy. As Co-Director of the MD Anderson Brain Metastasis Clinic he provides the vision and direction of clinical translational research at the Andrew M. McDougall Brain Metastasis Research Program. The primary focus of his research has been early phase studies of novel agents in melanoma. He has designed and conducted many Phase l and Phase ll studies, and recently led the Phase III trial leading to the FDA approval of the anti-LAG3 antibody relatlimab in combination with nivolumab. He is also interested in the study of special populations including patients with organ dysfunction and patients with melanoma brain metastases.   

Kelia Torres, M.D., Ph.D.
Professor, Department of Surgical Oncology
Joint Appointment, Professor, Department of Genomic Medicine

Dr. Torres specializes in providing surgical care to patients with sarcoma. As a scientist, she also leads a laboratory with the primary goal of understanding how high-grade soft tissue sarcomas, such as Malignant Peripheral Nerve Sheath Tumors (MPNSTs), grow and how they can be treated more efficiently. Dr. Torres' clinical expertise is in soft tissue sarcomas and neurofibromatosis type 1. Dr. Torres is the Co-Director of the Sarcoma Alliance for Collaboration Accelerator Program. She also serves as a scientific reviewer for the Department of Defense. View the Torres Laboratory webpage here.

Jennifer Wargo, M.D.
Professor, Department of Surgical Oncology

Dr. Jennifer Wargo is a physician-scientist and Professor of Surgical Oncology and Genomic Medicine at MD Anderson Cancer Center. Her research focuses on the mechanisms responsible for regulating response or resistance to cancer therapies, particularly immune checkpoint blockade (ICB). Dr. Wargo is renowned for her discoveries linking the gut microbiome to therapeutic responses in melanoma patients and for demonstrating that molecularly targeted therapies can sensitize tumor cells to immunotherapy, paving the way for more effective combination treatments. View the Wargo Laboratory page here.

Relevant Publications:
Randomized Placebo-Controlled, Biomarker-Stratified Phase Ib Microbiome Modulation in Melanoma: Impact of Antibiotic Preconditioning on Microbiome and Immunity. Seo YD, Glitza IC, Spencer CN, Wortman JR, Burton EM, Alayli FA, Loo CP, Gautam S, Damania A, Densmore J, Fairchild J, Cabanski CR, Wong MC, Peterson CB, Weiner B, Hicks N, Aunins J, McChalicher C, Walsh E, Tetzlaff MT, Hamid O, Ott PA, Boland GM, Sullivan RJ, Grossmann KF, Ajami NJ, LaVallee T, Henn MR, Tawbi HA, Wargo JA. Cancer Discov. 2024 Jul 1;14(7):1161-1175. doi: 10.1158/2159-8290.CD-24-0066. PMID: 38588588; PMCID: PMC11215408.

Using gut microorganisms to treat cancer. Seo YD, Ajami N, Wargo JA. Nat Med. 2023 Aug;29(8):1910-1911. doi: 10.1038/s41591-023-02460-y. PMID: 37420098.

From bugs to drugs: Bacterial 3-IAA enhances efficacy of chemotherapy in pancreatic cancer. Seo YD, Wargo JA. Cell Rep Med. 2023 May 16;4(5):101039. doi: 10.1016/j.xcrm.2023.101039. PMID: 37196631; PMCID: PMC10213830.

Wendy Woodward, M.D., Ph.D.
Professor and Chair, ad Department of Breast Radiation Oncology

Dr. Woodward is a physician scientist who runs an independently funded lab program focused on inflammatory breast cancer (IBC). She does clinical, translational, and basic science research and has mentored trainees and faculty at all levels. Her work has demonstrated the role of the microenvironment in the presentation of IBC, identified targets in mediating microenvironment mediation of radiation sensitivity and identified the role of cholesterol in progression of IBC. View the Woodward Laboratory page here. 

 

Relevant Publications:
Impact of Race on Cytokine Profiles in Patients with Triple-Negative Inflammatory Breast Cancer: An Exploratory Analysis. Presented at: Society of Surgical Oncology 2024 Annual Meeting. Chen JH, Meas S, Koupaei N, Roy D, Tidwell R, Woodward W, Lucci A., Mar 20-23, 2024 at Atlanta, GA

Impact of Postpartum Diagnosis on Survival Outcomes in Inflammatory Breast Cancer. Presented at The American Society of Breast Surgeons 25th Annual Meeting, Apr 10-14, 2024, Orlando, FL Chen JH, Tidwell R, Kai M, Johnson H, Lucci A, Woodward W.

Presence of Molecular Residual Disease After Pathologic Complete Response Among Patients with Inflammatory Breast Cancer. Presented at: 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31-Jun 4, 2024, Chicago, IL. Chen JH, Meas R, Sarli VN, Koupaei N, Upsahw J, Roy D, Valero V, Woodward WA, Lucci A.